Endpoints News 生物医药· ENDPOINTS·· 14 天前AI 评分36
Satellos 生物科学更改 Duchenne 研究主要终点
Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack risk
AI 导读
Satellos 生物科学更改其针对 Duchenne 肌营养不良症研究的主要终点,该研究涉及名为 forazapadin 的小分子药物。Amgen 的 Repatha 降低心脏病发作风险。
正文
Plus, news about MetaVia, Agios Pharmaceuticals and Inovio.
Satellos Bioscience changes Duchenne study primary endpoint: The company is studying a small-molecule drug called forazapadin aimed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news